Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | CCR2 | P41597 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733161 | 0.77 | TRPV4 (0.46) | TRPV4CCR2ALDH1A1 | |
| SCHEMBL27141810 | 0.76 | PSIP1 (0.37) | TRPV4SMN1; SMN2 | |
| SCHEMBL29907265 | 0.76 | PSIP1 (0.37) | TRPV4SMN1; SMN2 | |
| SCHEMBL91338 | 0.76 | P2RX7 (0.37) | P2RX7TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL31567040 | 0.76 | TRPV4 (0.42) | TRPV4CCR2TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15465525 | 0.75 | TRPV4 (0.40) | TRPV4CCR2ALDH1A1 | |
| SCHEMBL24755342 | 0.75 | CTRC (0.36) | P2RX7TSHR | |
| SCHEMBL2845042 | 0.72 | TAAR1 (0.36) | P2RX7TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL8412626 | 0.72 | PSIP1 (0.32) | — | |
| SCHEMBL31566968 | 0.71 | TRPV4 (0.50) | TRPV4CCR2L3MBTL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096637-A1 | SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2025-05-08 | — | — | WO | disclosed |